TABLE 3.

Univariable and multivariable Cox regression analyses assessing the effect of clinical/treatment‐related variables on progression‐free survival (PFS).

Models	Unit	Univariable		Multivariable
A. Overall group (27 events in N = 218)		HR (95%CI)	p	HR (95%CI)	p
Risk group	High vs. Inter (ref)	1.22 (0.56, 2.64)	0.616	1.90 (0.85, 4.26)	0.118
Number of tumours	≥2 vs. 1 (ref)	0.84 (0.33, 2.11)	0.704	‐‐	‐‐
Tumour size	≥3 cm vs. <3 cm (ref)	0.66 (0.28, 1.55)	0.337	‐‐	‐‐
Tumour focality	Multi vs. Uni (ref)	1.52 (0.65, 3.52)	0.335	‐‐	‐‐
Re‐TURBT	Yes vs. No (ref)	0.08 (0.01, 0.61)	0.015	0.11 (0.01, 0.80)	0.030
Adjuvant Treatment	BCG induc vs. None (ref)	0.38 (0.16, 0.90)	0.029	‐‐	‐‐
	BCG induc+main vs. None (ref)	0.10 (0.02, 0.44)	0.002	‐‐	‐‐
	BCG induc+main vs. induc (ref)	0.26 (0.06, 1.25)	0.093	‐‐	‐‐
	BCG/Chemo vs. None (ref)	0.27 (0.12, 0.57)	0.0007	0.32 (0.14, 0.70)	0.005

B. BCG group (10 events in N = 162 treated with BCG)		HR (95%CI)	p	HR (95%CI)	p
Risk group	High vs. Inter (ref)	2.43 (0.52, 11.46)	0.262	3.54 (0.71, 17.70)	0.124
Re‐TURBT	Yes vs. No (ref)	0.16 (0.02, 1.23)	0.077	0.15 (0.02, 1.17)	0.070
BCG modality	Induc+main vs. Induc (ref)	0.24 (0.05, 1.16)	0.076	0.18 (0.03, 0.98)	0.047

BCG: Bacillus Calmette–Guerin; Re: restaging; TURBT: transurethral resection of bladder tumour; MP: muscle present.

HR: Hazard ratio of progression for comparing groups. CI: confidence interval. p: p‐value testing HR = 1 from Wald test.

Note: Among 27 progression events, 19 with recurrence and progression simultaneously (within ±2 months) and eight with progression after recurrence (median elapsed time of 10.3 months [range: 6.7–58.3]). seventy‐one recurrence events without progression were censored in this analysis.